Ivan Hyep plans $283K sale of 12,500 Bicara shares

Form 144 for Bicara Therapeutics Inc. reports planned and recent Rule 144 sales of common stock by Ivan Hyep, including a new 12,500‑share sale tied to option exercises.

Rhea-AI Filing Summary

Bicara Therapeutics Inc. (BCAX) is the issuer for which a Form 144 notice has been filed regarding proposed sales of common stock for the account of Ivan Hyep. The filing indicates a planned sale of 12,500 common shares through UBS Financial Services Inc., with an aggregate market value of about $283,000.00 as of the filing. The shares are to be sold on or about September 8, 2026 and will be issued upon the exercise of stock options for cash. Over the prior three months, the same holder reported additional sales of 28,000 shares for $807,671.05 on July 8, 2026 and 12,500 shares for $349,591.25 on August 10, 2026.

Key Figures

Proposed shares to be sold: 12,500 shares Proposed aggregate market value: $283,000.00 Shares sold on July 8, 2026: 28,000 shares +3 more

6 metrics

Proposed shares to be sold 12,500 shares Common stock proposed for sale for the account of Ivan Hyep

Proposed aggregate market value $283,000.00 Estimated value of the 12,500 shares proposed to be sold

Shares sold on July 8, 2026 28,000 shares Common stock sold in the prior three months by the same holder

Proceeds from sale on July 8, 2026 $807,671.05 Value of 28,000 common shares sold by Ivan Hyep

Shares sold on August 10, 2026 12,500 shares Additional sale disclosed for the prior three months

Proceeds from sale on August 10, 2026 $349,591.25 Value of 12,500 common shares sold by Ivan Hyep

Key Terms

Rule 144, Exercise of stock options, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of stock options financial

"Common | 09/08/2026 | Exercise of stock options | Issuer"

attorney-in-fact regulatory

"Signature | /s/ UBS Financial Services Inc., as attorney-in-fact for Ivan Hyep"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Bicara Therapeutics Inc. (BCAX)?

The Form 144 reports that Ivan Hyep plans to sell 12,500 shares of Bicara Therapeutics Inc. common stock through UBS Financial Services Inc., with an indicated aggregate value of about $283,000.00, in connection with the cash exercise of stock options.

How many BCAX shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 12,500 shares of Bicara Therapeutics Inc. common stock. These shares are expected to be sold on or about September 8, 2026 after being issued upon the exercise of stock options for cash.

What recent BCAX share sales by Ivan Hyep are disclosed in the past three months?

The filing lists two prior sales: 28,000 shares of common stock sold on July 8, 2026 for $807,671.05 and 12,500 shares sold on August 10, 2026 for $349,591.25.

How will the 12,500 BCAX shares be acquired for sale?

The 12,500 Bicara Therapeutics Inc. shares are to be issued upon the exercise of stock options by Ivan Hyep, with the options being exercised for cash before the planned sale.

Who is handling the planned sale of BCAX shares disclosed in the Form 144?

The planned sale of 12,500 Bicara Therapeutics Inc. common shares is to be executed through UBS Financial Services Inc., which is identified as the broker handling the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:05 PM EDT Accepted by SEC EDGAR 09/08/2026 - 04:05 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002034668
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Bicara Therapeutics Inc.
SEC File Number	001-42271
Address of Issuer	116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116
Phone	617-468-4219
Name of Person for Whose Account the Securities are To Be Sold	Hyep Ivan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	12500	283000.00	66172934	09/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/08/2026	Exercise of stock options	Issuer			12500	09/08/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	07/08/2026	28000	807671.05
Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	08/10/2026	12500	349591.25

144: Remarks and Signature

Remarks
Date of Notice	09/08/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc., as attorney-in-fact for Ivan Hyep
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)